



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2411582 C 2009/10/27

(11)(21) **2 411 582**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2001/05/23
(87) Date publication PCT/PCT Publication Date: 2002/12/04
(45) Date de délivrance/Issue Date: 2009/10/27
(85) Entrée phase nationale/National Entry: 2002/12/04
(86) N° demande PCT/PCT Application No.: AT 2001/000162
(87) N° publication PCT/PCT Publication No.: 2001/093910
(30) Priorité/Priority: 2000/06/05 (AT A 978/2000)

(51) Cl.Int./Int.Cl. *A61K 33/04* (2006.01),
A61K 33/06 (2006.01)
(72) Inventeurs/Inventors:
KOSSLER, PETER, AT;
FUCHS, NORBERT, AT;
KUKLINSKI, BODO, DE;
SCHIEFER, RAIMUND, AT
(73) Propriétaire/Owner:
VIS-VITALIS LIZENZ-UND HANDELS GMBH, AT
(74) Agent: SMART & BIGGAR

(54) Titre : PROCEDE POUR AUGMENTER LE POTENTIEL D'ANTIOXYDATION DE SOLUTIONS AQUEUSES
CONTENANT DU SELENIUM

(54) Title: METHOD FOR INCREASING THE ANTIOXIDATIVE POTENTIAL OF SELENIUM-CONTAINING AQUEOUS
SOLUTIONS

(57) **Abrégé/Abstract:**

There is disclosed a method for increasing the antioxidant potential of selenium-containing aqueous solutions, wherein a selenium-containing aqueous solution is supplemented with pharmaceutically acceptable or food-compatible acids, selenium-containing preparations as well as the use of such preparations.



A b s t r a c t :

There is disclosed a method for increasing the antioxidant potential of selenium-containing aqueous solutions, wherein a selenium-containing aqueous solution is supplemented with pharmaceutically acceptable or food-compatible acids, selenium-containing preparations as well as the use of such preparations.

The invention relates to a method for increasing the antioxidant potential of selenium-containing aqueous solutions as well as pharmaceutically administrable or food-compatible selenium preparations.

All metabolic processes in organic living beings (plants, animals, humans) in the sense of growth, differentiation and energy processes constitute interplays between reductive and oxidative processes on the biochemical level. After all, these "redox procedures" are expressions of the electron transfer of biochemical reduction equivalents such as, e.g., $\text{NADH} + \text{H}^+$ (electron donor) to atmospheric molecular oxygen as an oxidizing agent (electron acceptor). The oxidation of our nutrients (fats, carbohydrates, proteins, oxygen) serves the permanent support and evolution of our biological structures.

On the other hand, it is exactly our cellular and subcellular structures, the tissues and organs formed thereof and, last but not least, each organic individuum which, in their entirety, are comprised of those structures (nutrients) which have to be constantly supplied externally for the support and evolution of living organisms, oxidized for the recovery of energy, but which, at the same time, also must serve to support the functional, anatomical and histological structures. Thus, these biological structures are actually as oxidable as those nutrients which have to be oxidized to conserve our vital energy. In order to inhibit the "autooxidation" of biological structures, the organic living organism uses endogenic and exogenic "antioxidants". Endogenic antioxidants include, inter alia, enzymes and enzyme systems such as superoxide dismutase, catalases, peroxydases, cholesterol and reduced glutathion, while exogenic antioxidants comprise, for instance, vitamin A, β -carotene, vitamin E, vitamin C or selenium.

The measure of the "antioxidant capacity", i.e., the readiness to transfer electrons to other atoms and molecules, is quantitatively expressed by what is called "reduction potential" (standard redox potential). The following Table gives a survey on

the standard redox potentials of some endogenic and exogenic antioxidants of organic living beings:

Standard redox potentials of some nutrients

E₀ (Volt)	System
+ 0.82	O ₂ /H ₂ O
+ 0.366 (basic environment)	selenite
+ 0.300	tocopherol (vitamin E)
+ 0.100	ubiquinone (coenzyme Q ₁₀)
+ 0.08	ascorbic acid
+ 0 (+0.16 to -0.02 V)	flavonoids
- 0.12	riboflavin (vitamin B ₂)
- 0.22	cystin/cystein
- 0.23	G SH/GSSG
- 0.29	thioctic acid (α -liponic acid)
- 0.32	NADH + H ⁺ /NAD
- 0.740 (acidic environment)	selenite

Antioxidants are, thus, atoms and molecules (for the human organism, primarily nutrient molecules and enzyme complexes) which react with metabolic radicals more rapidly than biological structures. Thus, they protect our cell, gene and connective tissue structures by trapping metabolic trigger sparks (radicals, peroxides) before the latter attack, for instance, unsaturated fatty acids of our biomembranes or sulphur-containing components of vital structural or enzymatic proteins. As is apparent from the above Table, certain elements such as, e.g., selenium change their standard redox potentials by changing the pH environment in which these compounds are dissolved.

Selenium is an essential micronutrient for higher animals and man. It has a protective function for proteins against oxidation caused, for instance, by glutathion peroxidase, which is contained in the active center of the aminoacid selenocystein. A selenium deficiency is associated with rheumatism and grey cataract, and the Keshan disease, which is common in some areas of China, is supposed to go back to selenium deficiency symptoms.

69812-16

3

Selenites are able to increase the effect of vitamin E and induce mercury and cadmium detoxication. A protective effect of selenium against carcinogens has also been reported.

On the other hand, selenium in higher concentrations has toxic effects, its toxicity supposedly going back to its ability to displace the sulphur contained in proteins. Excretion, as a rule, occurs via the kidney and the intestine in the form of selenates. Disorders of the human body will be caused if the daily nutrition contains more than 1 μg selenium/g (a minimum content of 0.02 μg selenium/g being required to prevent deficiency symptoms). Overall, the human body contains approximately 10 to 15 μg selenium.

Toxication will occur also in animals if animal nourishment contains more than 5 to 10 μg selenium/g, involving, for instance, growth inhibition, the loss of hair, the softening of horns and hoofs, and the loss of feathers with birds. Yet, selenium is necessary also for animals, when raising chickens, turkey hens and pigs, as well as to avoid specific diseases of domestic cattle, in particular sheep. Sodium selenite and sodium selenate are, therefore, required as supplements for mixed provender or for fertilizers of pastures, since the natural selenium contents of animal and vegetable feed are frequently insufficient, or the element is released in an insufficient manner.

The present invention improves selenium-containing preparations and uses them in a food/feed-technological context as well as a pharmaceutical context, and to enhance their activities in these fields.

In accordance with the invention, this is achieved by a method for increasing the antioxidant potential of selenium-containing aqueous solutions, which is characterized in that a selenium-containing aqueous solution is supplemented with pharmaceutically acceptable or food-compatible acids.

69812-16

3a

In one aspect, the invention provides use of a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any
5 mixture thereof, for the production of a medicament for the prevention or treatment of a viral disease.

In a further aspect, the invention provides use of a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid,
10 acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for the prevention or treatment of a viral disease.

In a still further aspect, the invention provides use of a selenite-containing aqueous solution, supplemented
15 with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for the production of a medicament for the prevention or treatment of a pigmented mole.

In a yet further aspect, the invention provides
20 use of a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for the prevention or treatment of a pigmented mole.

25 In another aspect, the invention provides a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for use in the production of a medicament
30 for the prevention or treatment of a viral disease.

69812-16

3b

In still another aspect, the invention provides a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for use in the prevention or treatment of a viral disease.

In yet another aspect, the invention provides a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for use in the production of a medicament for the prevention or treatment of a pigmented mole.

The invention also provides a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for use in the prevention or treatment of a pigmented mole.

The invention also provides a pharmaceutical composition, comprising a pharmaceutically acceptable form of selenium as selenite, wherein the composition is a gel or emulsion and contains a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof.

The invention also provides a commercial package comprising a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, or a composition as defined above, and associated therewith instructions for the use thereof in the prevention or treatment of a viral infection.

69812-16

3c

The invention also provides a commercial package comprising a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a
5 fruit acid or any mixture thereof, or a composition as defined above, and associated therewith instructions for the use thereof in the prevention or treatment of a pigmented mole.

It has been shown that a decrease of the pH of selenium-containing solutions, in particular sodium selenite and selenate solutions, exhibit a strongly increased antioxidant potential as compared to non-pH-reduced solutions. The solutions prepared according to the invention also show surprising therapeutic effects, primarily with diseases induced by radicals and peroxides.

Preferably, a selenite or selenate solution is, therefore, used as said selenium-containing aqueous solution.

Acidifying agents for the selenium-containing solution comprise, in particular, acidifying agents that are generally recognized as safe to both man and animal, such as, e.g., citric acid, acetic acid, malic acid, carbonic acid, various fruit acids and mixtures thereof.

The present invention also relates to a preparation comprising

- a pharmaceutically administrable or food-compatible form of selenium, namely selenite or selenate, and
- a pharmaceutically acceptable or food-compatible acid selected from citric acid, acetic acid, malic acid, carbonic acid, various fruit acids and mixtures thereof.

The preparation according to the invention has an enhanced antioxidant potential, thus exhibiting positive properties for both man and animal when applied in a food-technological and feed-technological context. In connection with the pharmaceutical use of selenium compounds, also the pharmaceutical action is enhanced by the preparation according to the invention, or even new pharmaceutical applications for selenium compounds are opened up.

In a preferred manner, acidification of the selenium-containing agent provides a pH of below 7.0, preferably below 5.0, in particular below 4.0. Agents according to the invention which are particularly preferred have a pH ranging from 6.0 to 2.0, in particular 3.0 to 2.5.

In the context of the preparation according to the invention, selenium is made available in the form of selenite or in the form of selenate. For different purposes of use, the dimethylselenide, selenomethionin, selenocystein forms or mixtures of these forms are suitable as well.

The preparation according to the invention may be provided not only in an aqueous solution. Preferred other forms comprise gels or emulsions, which have proved to be excellently suitable, in particular, for pharmaceutical applications, enabling local topical application.

It goes without saying that the preparation according to the invention may additionally contain auxiliary substances like buffering agents, dyes, stabilizing agents or carrier substances and/or further active components such as, e.g., antibiotics, antiviral agents, antimyotics, analgetics or anti-inflammatory agents, said auxiliary substances being also usable in any desired combinations. The respective type of auxiliary substance and/or additional active component is a function of the respective use in each individual case.

The preparation according to the invention is particularly apt for pharmaceutical uses. Yet, also its use as a foodstuff or food supplement or as a feedstuff or feed supplement is preferred.

During the pharmaceutical application of the preparation according to the invention, it was surprisingly found that it is, above all, effective in the prevention or treatment of peroxidic and free-radical diseases.

In a preferred manner, the preparation according to the invention is, therefore, used to prepare a drug designed to prevent or treat viral diseases, preferably herpes infections, in particular herpes simplex infections. On the other hand, the preparation according to the invention also has been shown to be extremely active in the prevention or treatment of pigmental moles (caused by lipofuszin depositions).

The invention will now be explained in more detail by way of the following examples to which it is, however, not limited.

Example 1: Preparation of an acidified sodium selenite solution

An acidified sodium selenite solution having the following composition (per 100 ml) was prepared:

sodium selenite pentahydrate	0.111 g
maltodextrin	0.5 g
citrus aroma	0.1 g
citric acid	0.5 g
food dye	0.01 g
potassium sorbate	0.1 g
sodium benzoate	0.05 g
aqua destillata	99.29 g

Example 2: Treatment of herpes simplex infections

Twelve adult patients (seven female and five male patients) as well as eight children (four females and four males) diagnosed to suffer from stomatitis herpetica/aphtosa were treated buccally with five drops five times a day (children receiving the solution at a ten-fold dilution) and, at the same time, externally (the affected sites being dabbed with the droplets five times a day), usually over a period of seven days. Seven out of eight children, in addition to the antioxidant selenium therapy, were prescribed local anesthetics and/or antibiotics and/or antimycotics and/or pain-relieving and anti-inflammatory drugs, but no additional antiviral therapy.

Nine out of the twelve adults were treated exclusively with the strongly antioxidant selenium drops, one of the twelve patients receiving an antiviral drug (aciclovir) in addition to the drops. The results are illustrated in the Table below.

Herpes labialis therapy

Patient No.	Sex	Incidence	previous treatment	side-effects	Treatment results
1	m	1y	local ointment therapy	none	1
2	m	nth.	aciclovir	none	1
3	m	3-5y	aciclovir	none	1
4	f	3y	aciclovir	none	1
5	m	-	-	-	1
6	f	3y	famvir	none	2
7	f	nth.	aciclovir	none	1
8	f	3-5y	aciclovir	none	1
9	f	3y	aciclovir	none	1
10	f	3y	aciclovir	none	1

Stomatitis herpetica/aphtosa therapy

Patient No.	Sex	Incidence	previous treatment	side-effects	Treatment results
11	m	-	xylocain	none	1
12	f	-	-	none	2
13	f	-	-	none	1
14	m	-	-	none	1
15	m	-	-	none	1
16	f	-	-	none	2
17	m	-	-	none	1
18	f	-	-	none	2
19	f	-	-	none	2
20	m	nth.	-	none	2

m = male

f = female

nth. = monthly

1y = 1 x per year

2y = 2 x per year

3y = 3 x per year

3-5y = 3 to 5 x per year

1 = very good

2 = good

3 = insufficient

The examination reports of the examining physician showed excellent therapeutic results (itching disappeared and vesicles healed) already after three to seven days in nineteen out of twenty cases. Those male and female patients who suffered from herpes relapses, after the buccal and external application of the drops showed markedly improved relapse rates (extended intervals without relapses), or the complete disappearance of relapses, as compared to an aciclovir therapy.

Example 3: Treatment of pigment moles

Pigment moles (socalled age spots) are due to an elevated deposition of radically and peroxidically destroyed protein, fatty acid and membrane fat structures in the subcutaneous tissue, appearing as locally delimited light- to dark-brown discolorations of apprximately pin size. Three adult persons (two female and one male persons) applied the selenium droplets described (by ribbing in five to ten drops five times a day on the affected sites on the back of the hand) over a period of two months. The application led to a marked reduction of the number of pigment moles and to a brightening of dark pigment moles, respectively.

69812-16

9

CLAIMS:

1. Use of a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a
5 fruit acid or any mixture thereof, for the production of a medicament for the prevention or treatment of a viral disease.
2. Use of a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which
10 is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for the prevention or treatment of a viral disease.
3. The use according to claim 1 or 2, wherein the viral disease is a herpes infection.
- 15 4. The use according to claim 3, wherein the herpes infection is a herpes simplex infection.
5. Use of a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a
20 fruit acid or any mixture thereof, for the production of a medicament for the prevention or treatment of a pigmented mole.
6. Use of a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which
25 is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for the prevention or treatment of a pigmented mole.
7. The use according to claim 1 or 5, wherein the medicament is in the form of a gel or emulsion, which is
30 used locally.

69812-16

10

8. A selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for use in the production
5 of a medicament for the prevention or treatment of a viral disease.

9. A selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a
10 fruit acid or any mixture thereof, for use in the prevention or treatment of a viral disease.

10. The solution according to claim 8 or 9, wherein the viral disease is a herpes infection.

11. The solution according to claim 10, wherein the
15 herpes infection is a herpes simplex infection.

12. A selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, for use in the production
20 of a medicament for the prevention or treatment of a pigmented mole.

13. A selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a
25 fruit acid or any mixture thereof, for use in the prevention or treatment of a pigmented mole.

14. The solution according to claim 8 or 12, wherein the medicament is in the form of a gel or emulsion, which is used locally.

69812-16

11

15. A pharmaceutical composition, comprising a pharmaceutically acceptable form of selenium as selenite, wherein the composition is a gel or emulsion and contains a pharmaceutically acceptable acid which is citric acid,
5 acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof.

16. Use of the composition according to claim 15, as defined in any one of claims 1 to 6.

17. The composition according to claim 15, for the use
10 as defined in any one of claims 8 to 13.

18. A commercial package comprising a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid, acetic acid, malic acid, carbonic acid, a fruit acid or any
15 mixture thereof, or a composition according to claim 15, and associated therewith instructions for the use thereof in the prevention or treatment of a viral infection.

19. The commercial package according to claim 18, wherein the viral disease is a herpes infection.

20. The commercial package according to claim 19, wherein the herpes infection is a herpes simplex infection.

21. A commercial package comprising a selenite-containing aqueous solution, supplemented with a pharmaceutically acceptable acid which is citric acid,
25 acetic acid, malic acid, carbonic acid, a fruit acid or any mixture thereof, or a composition according to claim 15, and associated therewith instructions for the use thereof in the prevention or treatment of a pigmented mole.